Avience Biomedicals Stock Soars to Upper Circuit on Debut, Listing at 90% Premium Over IPO Price
Avience Biomedicals made a blockbuster market debut on Thursday after hitting the upper circuit limit, trading significantly higher than its issue price. The Noida-based diagnostics solutions provider surged immediately following its listing on the NSE Emerge platform.The company's stock was listed at ₹414.95, reaching the upper circuit limit soon after the initial listing. This dramatic performance reflected a substantial gain of 90 percent from the IPO price of ₹208 per share.
Details of The High-Performing Debut
The Initial Public Offering (IPO) for Avience Biomedicals had garnered immense investor interest. It was subscribed to an impressive 365.06 times on June 22, marking a strong response from the market ahead of the listing day.Avience Biomedicals approached the capital markets with plans to raise ₹30.2 crore through an issuance of 14.53 lakh shares. The price band for the IPO had been strategically set between ₹196 and ₹208 per share.
Operational Scope and Market Positioning
The company operates as a critical player in the B2B and B2C medical sector. Avience manufactures in-vitro diagnostic (IVD) products and various essential medical devices.It serves pathology labs, microbiology labs, hospitals, and specialized research centers across its customer base. Beyond manufacturing capabilities, the company also functions as a distributor and trader of medical equipment.
Pre-IPO Investment Activities
Ahead of the public listing, Avience Biomedicals had successfully raised an initial amount of ₹8.52 crore from four anchor investors. These anchor investors included Meru Investment Fund, Shine Star Build Cap, Fortune Hands Growth Fund Scheme, and Sanshi Funds. A total allocation of 4.09 lakh shares was given to these anchors at the IPO price of ₹208 per share.Planned Utilization of IPO Proceeds
The proceeds raised from the IPO are earmarked for strategic expansion and working capital needs. Of the funds raised, a significant portion of ₹15.95 crore is dedicated to establishing a new manufacturing unit. This facility will be located in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh.Furthermore, Avience Biomedicals plans to allocate ₹8.25 crore toward fulfilling its working capital requirements. The remaining funds are designated for general corporate purposes, supporting continued growth and operations.
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.